Biogen’s diranersen slows Alzheimer’s clinical decline by 38% at two years in Phase 2 study
BIIB•Biogen said diranersen slowed clinical decline by 38% at two years in its Phase 2 study of early Alzheimer’s disease. The 60 mg twice-yearly regimen showed the largest treatment effects, with no new safety signals reported through two years.
1. Two-year findings
Biogen announced Phase 2 CELIA results showing diranersen slowed clinical decline in early Alzheimer’s disease, with greater benefit at two years. The findings came from an ongoing open-label extension comparing participants who continued treatment with those initially assigned to placebo. The 60 mg twice-yearly regimen showed the largest treatment effects, and no new safety signals emerged through two years. The results support further evaluation in a Phase 3 trial; diranersen remains investigational and has no regulatory approval.




